Skip to Content
Merck
CN
All Photos(1)

Documents

R7757

Sigma-Aldrich

Red Blood Cell Lysing Buffer Hybri-Max™

liquid, sterile-filtered, suitable for hybridoma

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
RBC Lysing Buffer
UNSPSC Code:
12352207
NACRES:
NA.75

sterility

sterile-filtered

Quality Level

400

form

liquid

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

Application

Recommended for use by adding 1 mL of buffer to a cell pellet (cell pellet = 1 spleen or 100-200 million cells). Gently mix for 1 minute. Dilute the buffer with 15-20 mL of medium or salt solution. Centrifuge at 250-500 × g for 7 minutes and decant the supernatant. Cells may be diluted and prepared for counting or fusion. If lysis is incomplete, steps 1-4 may be repeated.

Biochem/physiol Actions

Red Blood Cell Lysing Buffer has been developed for use in hybridoma protocols to remove red blood cells from mouse splenocyte suspensions before fusion. It is also useful in systems where it may be desirable to remove red blood cells from cell suspensions, such as whole blood.

Components

Contains 8.3 g/L ammonium chloride in 0.01 M Tris-HCl buffer.

Other Notes

Note: This product is intended for the removal of red blood cells from mice. This product may not be appropriate for the lysis of red blood cells of other animals. The suitability of the product in any application other than mouse splenocytes must be determined by the researcher.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. Is the BSA standard supplied with Product B6916, Bradford Reagent?

    No, we do not supply the BSA standard with this reagent. We recommend using one of the following products: Protein Standard (BSA) Solution, (2 mg/mL), Product No. P0834 or Protein Standard (BSA) Solution, (1 mg/mL), Product No. P0914, if lower concentrations of protein are to be measured.

  3. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  4. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  5. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  6. Can Product R7757, Red Blood Cell Lysing Buffer Hybri-Max™, be used to lyse cells that are trapped in whole tissue preparations?

    Unfortunately, we have not verified the suitability of this lysis buffer for using with tissue samples and do not have a protocol.   

  7. In step 3 of your usage sheet for Product R7757, Red Blood Cell Lysing Buffer Hybri-Max™, you say to dilute this buffer with medium or "salt solution". What salt solution is appropriate?

    Any balanced salt solution such as DPBS (Dulbecco's phosphate buffered saline) or HBSS (Hank's Balanced Salt Solution) may be used to dilute the buffer when following this procedure.

  8. Since you do not recommend Product R7757, Red Blood Cell Lysing Buffer Hybri-Max™, for treating whole blood, what protocol and products do you recommend for red cell lysis in a sample of whole blood?

    The following is a suggested protocol:1. Centrifuge to remove plasma. A volume of 0.2 mL of whole blood will yield approximately 0.1 mL of packed cells. Add 0.1ml of 1X buffer such as HBSS (Hanks' balanced salt solution, Product No. H1641) or DPBS (Dulbecco's phosphate buffered saline solution, Product No. D1283), to 0.1 mL of the pelleted cells and resuspend the pellet.2. Add 1-2 mls of 0.1X diluent (or water) and quickly mix cells using the same pipette.3. After 15 seconds, quickly add a volume of 2X diluent in the amount used in step 2 and mix thoroughly.  Dilute further with 1X diluent.  Wash cells once with buffer.

  9. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Christopher J M Piper et al.
Cell reports, 29(7), 1878-1892 (2019-11-14)
Regulatory B cells (Bregs) play a critical role in the control of autoimmunity and inflammation. IL-10 production is the hallmark for the identification of Bregs. However, the molecular determinants that regulate the transcription of IL-10 and control the Breg developmental
John M Furgason et al.
Mutagenesis, 29(5), 341-350 (2014-08-12)
Next generation sequencing has become a powerful tool in dissecting and identifying mutations and genomic structural variants that accompany tumourigenesis. Sequence analysis of glioblastoma multiforme (GBM) illustrates the ability to rapidly identify mutations that may affect phenotype. Approximately 50% of
H Guan et al.
Oncogenesis, 4, e166-e166 (2015-09-08)
Recent advances have highlighted profound roles of FOXO transcription factors, especially FOXO1, in bone development and remodeling. The regulation of bone development by FOXOs seems to be stage-specific or context dependent. FOXOs promote maintenance and differentiation of early progenitors of
Iris Boraschi-Diaz et al.
Cytotechnology, 68(1), 105-114 (2014-09-24)
Osteoclasts are responsible for physiological bone remodeling as well as pathological bone destruction in osteoporosis, periodontitis and rheumatoid arthritis, and thus represent a pharmacological target for drug development. We aimed to characterize and compare the cytokine-induced osteoclastogenesis of bone marrow
Lixing Zhang et al.
Cellular signalling, 29, 41-51 (2016-11-05)
Recent evidence suggests that mammary cells expressing R-spondin receptor and Wnt pathway regulator Lgr5, regarded as a stem cell marker in multiple tissues, might represent mammary stem cells (MaSCs). Whether L gr5 marks a multipotent subpopulation of Lin-CD24low/medCD49fhigh MaSCs remains
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service